» Authors » Miikka Vikkula

Miikka Vikkula

Explore the profile of Miikka Vikkula including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 182
Citations 5662
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Gucciardo F, Lebeau A, Pirson S, Buntinx F, Ivanova E, Blacher S, et al.
Circulation . 2025 Mar; PMID: 40035133
Background: Lymphedema is an incurable disease associated with lymphatic dysfunction that causes tissue swelling and fibrosis. We investigated whether lymphedema could be attenuated by interfering with uPARAP (urokinase plasminogen activator...
2.
Holm A, Graus M, Wylie-Sears J, Tan J, Alvarez-Harmon M, Borgelt L, et al.
J Clin Invest . 2025 Feb; PMID: 39998898
Infantile hemangioma (IH) is the most common tumor in children and a paradigm for pathological vasculogenesis, angiogenesis, and regression. Propranolol, the mainstay treatment, inhibits IH vessel formation via a β-adrenergic...
3.
Copelli M, Atique-Tacla M, Pairet E, Correia-Costa G, Henrique de Souza T, Monlleo I, et al.
J Craniomaxillofac Surg . 2025 Jan; 53(4):370-376. PMID: 39855980
This study describes the results of whole exome sequencing in the etiological investigation and genetic counseling of families presenting with non-syndromic oral clefts with vertical transmission recorded in the Brazilian...
4.
Seront E, Queisser A, Boon L, Vikkula M
Hematology Am Soc Hematol Educ Program . 2024 Dec; 2024(1):700-708. PMID: 39644020
Vascular malformations, which result from anomalies in angiogenesis, include capillary, lymphatic, venous, arteriovenous, and mixed malformations and affect specific vessel types. Historically, treatments such as sclerotherapy and surgery have shown...
5.
Ranji P, Pairet E, Helaers R, Bayet B, Gerdom A, Gil-da-Silva-Lopes V, et al.
Eur J Hum Genet . 2024 Nov; 33(1):38-43. PMID: 39506048
The pathophysiological basis of non-syndromic orofacial cleft (NsOFC) is still largely unclear. However, exome sequencing (ES) has led to identify several causative genes, often with reduced penetrance. Among these, the...
6.
Andreoti T, Maiolo M, Tuleja A, Doring Y, Schaller A, Vassella E, et al.
Am J Med Genet A . 2024 Oct; 197(2):e63883. PMID: 39376044
PIK3CA variants are known to cause vascular malformations. We were interested in studying the phenotypic spectrum, the location within the PIK3CA gene, and the variant allele frequency (VAF) of somatic...
7.
Revencu N, Eijkelenboom A, Bracquemart C, Alhopuro P, Armstrong J, Baselga E, et al.
Orphanet J Rare Dis . 2024 Oct; 19(1):369. PMID: 39375751
No abstract available.
8.
Seront E, Biard J, Van Damme A, Revencu N, Lengele B, Schmitz S, et al.
Nat Cardiovasc Res . 2024 Aug; 2(6):595-599. PMID: 39195878
Sirolimus, by targeting the mammalian target of rapamycin (mTOR) pathway, has demonstrated efficacy on lymphatic malformations (LMs) in adults and neonates. The current hypothesis is that the earlier the lesion...
9.
Boon L, Dekeuleneer V, Coulie J, Marot L, Bataille A, Hammer F, et al.
Nat Cardiovasc Res . 2024 Aug; 1(6):562-567. PMID: 39195866
Arteriovenous malformations (AVMs) are fast-flow lesions that may be destructive and are the most difficult-to-treat vascular anomalies. Embolization followed by surgical resection is commonly used; however, complete resection is rarely...
10.
Seront E, Hermans C, Boon L, Vikkula M
J Thromb Haemost . 2024 Aug; 22(11):2961-2975. PMID: 39097232
Vascular malformations, which arise from anomalies in angiogenesis, encompass capillary, lymphatic, venous, arteriovenous, and mixed malformations, each affecting specific vessel types. Historically, therapeutic options such as sclerotherapy and surgery have...